1. Medication holidays in osteoporosis: evidence-based recommendations from the Italian guidelines on ‘Diagnosis, risk stratification, and continuity of care of fragility fractures’ based on a systematic literature review
- Author
-
Migliaccio, Silvia, Moretti, Antimo, Biffi, Annalisa, Ronco, Raffaella, Porcu, Gloria, Adami, Giovanni, Alvaro, Rosaria, Bogini, Riccardo, Caputi, Achille Patrizio, Cianferotti, Luisella, Frediani, Bruno, Gatti, Davide, Gonnelli, Stefano, Lenzi, Andrea, Leone, Salvatore, Nicoletti, Tiziana, Paoletta, Marco, Pennini, Annalisa, Piccirilli, Eleonora, Michieli, Raffaella, Tarantino, Umberto, Rossini, Maurizio, Corrao, Giovanni, Brandi, Maria Luisa, Iolascon, Giovanni, Migliaccio, Silvia, Moretti, Antimo, Biffi, Annalisa, Ronco, Raffaella, Porcu, Gloria, Adami, Giovanni, Alvaro, Rosaria, Bogini, Riccardo, Caputi, Achille Patrizio, Cianferotti, Luisella, Frediani, Bruno, Gatti, Davide, Gonnelli, Stefano, Lenzi, Andrea, Leone, Salvatore, Nicoletti, Tiziana, Paoletta, Marco, Pennini, Annalisa, Piccirilli, Eleonora, Michieli, Raffaella, Tarantino, Umberto, Rossini, Maurizio, Corrao, Giovanni, Brandi, Maria Luisa, and Iolascon, Giovanni
- Subjects
adherence, bisphosphonates, compliance, discontinuation, fragility fractures, medication vacation, osteoporosis, persistence - Abstract
Background: Noncommunicable, chronic diseases need pharmacological interventions for long periods or even throughout life. The temporary or permanent cessation of medication for a specific period, known as a ‘medication holiday,’ should be planned by healthcare professionals. Objectives: We evaluated the association between continuity (adherence or persistence) of treatment and several outcomes in patients with fragility fractures in the context of the development of the Italian Guidelines. Design: Systematic review. Data Sources and Methods: We systematically searched PubMed, Embase, and the Cochrane Library up to November 2020 for randomized clinical trials (RCTs) and observational studies that analyzed medication holidays in patients with fragility fracture. Three authors independently extracted data and appraised the risk of bias of the included studies. The quality of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation methodology. Effect sizes were pooled in a meta-analysis using random effects models. Primary outcomes were refracture and quality of life; secondary outcomes were mortality and treatment-related adverse events. Results: Six RCTs and nine observational studies met our inclusion criteria, ranging from very low to moderate quality. The adherence to antiosteoporotic drugs was associated with a lower risk of nonvertebral fracture [relative risk (RR) 0.42, 95% confidence interval (CI) 0.20–0.87; three studies] than nonadherence, whereas no difference was detected in the health-related quality of life. A reduction in refracture risk was observed when continuous treatment was compared to discontinuous therapy (RR 0.49, 95% CI 0.25–0.98; three studies). A lower mortality rate was detected for the adherence and persistence measures, while no significant differences were noted in gastrointestinal side effects in individuals undergoing continuous versus discontinuous treatment. Conclusion: Our findings suggest that clinicians should promote adherence and persistence to antiosteoporotic treatment in patients with fragility fractures unless serious adverse effects occur.
- Published
- 2023